Venezuela (Bolivarian Republic of)Tuberculosis profile
Population  2014 31 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.54 (0.54–0.55) 1.8 (1.8–1.8)
Mortality (HIV+TB only) 0.12 (0.083–0.17) 0.4 (0.27–0.55)
Prevalence  (includes HIV+TB) 8.8 (3.8–16) 29 (13–52)
Incidence  (includes HIV+TB) 7.3 (6.4–8.3) 24 (21–27)
Incidence (HIV+TB only) 0.7 (0.6–0.81) 2.3 (2–2.6)
         
Case detection, all forms (%) 87 (77–99)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.9–2.6) 13 (11–15)
MDR-TB cases among notified pulmonary
TB cases
85 (45–130) 70 (58–81)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 526   243
Pulmonary, clinically diagnosed 1 458   80
Extrapulmonary 1 079   6
       
Total new and relapse 6 392    
Previously treated, excluding relapses 223    
Total cases notified 6 615    
Among 6 392 new and relapse cases:
415 (6%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 266 (8%) 186 (34%) 462
Laboratory-confirmed RR-/MDR-TB cases     26
Patients started on MDR-TB treatment ***     26
TB/HIV 2014 Number (%)
TB patients with known HIV status 4 613 (70)
HIV-positive TB patients 482 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 166 (34)
HIV-positive TB patients on antiretroviral therapy (ART) 398 (83)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (81) 6 481
Previously treated cases, excluding relapse, registered in 2013 (59) 237
HIV-positive TB cases, all types, registered in 2013 (80) 581
RR-/MDR-TB cases started on second-line treatment in 2012 (52) 21
XDR-TB cases started on second-line treatment in 2012   1
Laboratories 2014  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 1.6
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 1.3
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-06 Data: www.who.int/tb/data